Abstract:Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain reaction, beads, emulsion, amplification, and magnetics (BEAMing), tagged-amplicon deep sequencing (TAm-Seq), cancer personalized profiling by deep sequencing (CAPP-Seq), whole genome bisulfite sequencing (WGBS-Seq), whole exome sequencing (WES), and whole genome sequencing (WGS). CTCs have been isolated using biomarker-based cell capture, and positive or negative enrichment based on biophysical and other properties. ctDNA/cfDNA and CTCs are being exploited in a variety of clinical applications: differentiating unique immune checkpoint blockade response patterns using serial samples; predicting immune checkpoint blockade response based on baseline liquid biopsy characteristics; predicting response and resistance to targeted therapy and chemotherapy as well as immunotherapy, including CAR-T cells, based on serial sampling; assessing shed DNA from multiple metastatic sites; assessing potentially actionable alterations; analyzing prognosis and tumor burden, including after surgery; interrogating difficult-to biopsy tumors; and detecting cancer at early stages. The latter can be limited by the small amounts of tumor-derived components shed into the circulation; furthermore, cfDNA assessment in all cancers can be confounded by clonal hematopoeisis of indeterminate potential, especially in the elderly. CTCs can be technically more difficult to isolate that cfDNA, but permit functional assays, as well as evaluation of CTC-derived DNA, RNA and proteins, including single-cell analysis. Blood biopsies are less invasive than tissue biopsies and hence amenable to serial collection, which can provide critical molecular information in real time. In conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.

Cancer metabolites: promising biomarkers for cancer liquid biopsy

Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring

Research Progress on Tumor Metabolic Biomarkers in Liquid Biopsy of Lung Cancer

Liquid biopsies for cancer: From bench to clinic

Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application

Blood-based Tumor Markers in Lung Cancer

The functional and clinical roles of liquid biopsy in patient-derived models

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

Liquid biopsy in cancer current: status, challenges and future prospects

Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy

Metabolomics in Cancer Biomarker Research

Biotransformation-based Metabolomics Profiling Method for Determining and Quantitating Cancer-Related Metabolites.

Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer

Metabolomics: a Revolution for Novel Cancer Marker Identification.

Liquid biopsy: current technology and clinical applications

Refining Cancer Management Using Integrated Liquid Biopsy

Liquid biopsy: paving a new avenue for cancer research

Liquid Biopsy in the Clinical Management of Cancers

Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring